Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of Oral NNC0113-2023 in Healthy Men
NCT03617081Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Aug 2018
- Primary completion
- Dec 2018
- Modality
- Peptides, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing NNC0113-2023 with Placebo (2 arms). Primary endpoint: Number of treatment emergent adverse events. Started Aug 2018; status: completed.
02
Drugs
NNC0113-2023
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03617081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03617081.